RAPT Therapeutics, Inc. (RAPT)
| Previous Close | 8.33 |
| Open | 8.39 |
| Bid | 8.31 x 100 |
| Ask | 8.35 x 200 |
| Day's Range | 8.20 - 8.44 |
| 52 Week Range | 6.86 - 27.35 |
| Volume | |
| Avg. Volume | 1,424,090 |
| Market Cap | 289.186M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.05 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.13 |
GlobeNewswireRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subset of patients with HPV+ disease - Median duration of treatment in responders was 19.6 months at the time of data cutoff SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discover
Insider MonkeyWhat Makes RAPT Therapeutics (RAPT) an Investment Choice?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned 9.15% (net), compared to a 12.75% return for the Russell 2000 Growth Index. For the year, the fund returned 15.96% (net) compared to […]
ZacksShould You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
